Syndrome Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.30 M
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 23.80%
- Profit Growth 27.05%
- Ebitda 24.25%
- Net Worth 26.36%
- Total Assets -9.86%
About Syndrome Pharmaceuticals
Syndrome Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 May 2009 and has a history of 15 years and nine months. Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Sunil Kumar, Kulbhaskar, and Rajesh Kumar serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230BR2009PTC014515
- Company No.
014515
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 May 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Syndrome Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Kumar  | Managing Director | 18-May-2009 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kulbhaskar | Director | 20-Oct-2014 | Current |
| Rajesh Kumar | Additional Director | 07-Mar-2016 | Current |
Financial Performance of Syndrome Pharmaceuticals.
Syndrome Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.8% increase. The company also saw a substantial improvement in profitability, with a 27.05% increase in profit. The company's net worth Soared by an impressive increase of 26.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syndrome Pharmaceuticals?
In 2021, Syndrome Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Didhirsha Private LimitedKulbhaskar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Syndrome Pharmaceuticals?
Unlock and access historical data on people associated with Syndrome Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syndrome Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syndrome Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
